Misha Nossov - VBI Vaccines Senior Europe
Executive
Misha Nossov is Senior Europe of VBI Vaccines
| Phone | 617 830 3031 |
| Web | https://www.vbivaccines.com |
VBI Vaccines Management Efficiency
The company has return on total asset (ROA) of (0.2915) % which means that it has lost $0.2915 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.1959) %, meaning that it created substantial loss on money invested by shareholders. VBI Vaccines' management efficiency ratios could be used to measure how well VBI Vaccines manages its routine affairs as well as how well it operates its assets and liabilities.VBI Vaccines currently holds 53.04 M in liabilities with Debt to Equity (D/E) ratio of 0.32, which is about average as compared to similar companies. VBI Vaccines has a current ratio of 2.24, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about VBI Vaccines' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Thomas Englese | Tonix Pharmaceuticals Holding | 51 | |
| Hilda Maibach | Annovis Bio | N/A | |
| William CPA | Annovis Bio | 60 | |
| Sue Evans | Aurinia Pharmaceuticals | N/A | |
| Dr MBA | Tonix Pharmaceuticals Holding | 66 | |
| John Schembri | Akero Therapeutics | 63 | |
| Karen Brunke | Jaguar Animal Health | 73 | |
| Alison Moore | Allogene Therapeutics | 57 | |
| Joseph Reilly | Ardelyx | 52 | |
| John Niles | GeoVax Labs | N/A | |
| Mike Kelliher | Ardelyx | 48 | |
| James Harrell | Aurinia Pharmaceuticals | 54 | |
| Andrea Christopher | Aurinia Pharmaceuticals | N/A | |
| Michael Martin | Aurinia Pharmaceuticals | 53 | |
| Sean Tucker | Vaxart Inc | 57 | |
| DeDe Sheel | Aurinia Pharmaceuticals | N/A | |
| Barbra Sasu | Allogene Therapeutics | N/A | |
| Premchandran Ramiya | Aurinia Pharmaceuticals | 64 | |
| Rajesh Kapoor | Vaxart Inc | N/A | |
| David JD | Akero Therapeutics | N/A | |
| MBA CPC | BridgeBio Pharma | 50 | |
Management Performance
| Return On Equity | -4.2 | |||
| Return On Asset | -0.29 |
VBI Vaccines Leadership Team
Elected by the shareholders, the VBI Vaccines' board of directors comprises two types of representatives: VBI Vaccines inside directors who are chosen from within the company, and outside directors, selected externally and held independent of VBI. The board's role is to monitor VBI Vaccines' management team and ensure that shareholders' interests are well served. VBI Vaccines' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, VBI Vaccines' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Adam Buckley, Vice President - Operations and Project Management | ||
| FRCPC MD, Chief Officer | ||
| FCMA FCMA, CEO Pres | ||
| Christopher McNulty, CFO and Head of Business Development | ||
| Nicole Anderson, Director Relations | ||
| Avi Mazaltov, Global SciVac | ||
| Misha Nossov, Senior Europe | ||
| David Anderson, Chief Scientific Officer | ||
| Jeffery FCMA, CEO President | ||
| Nell Beattie, Chief Officer | ||
| Athena Kartsaklis, Principal Financial and Accounting Officer, Senior Vice President - Finance, Chief Compliance Officer, Corporate Controller | ||
| John Dillman, Chief Officer |
VBI Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is VBI Vaccines a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -4.2 | |||
| Return On Asset | -0.29 | |||
| Operating Margin | (9.68) % | |||
| Current Valuation | 38.92 M | |||
| Shares Outstanding | 28.68 M | |||
| Shares Owned By Insiders | 6.76 % | |||
| Shares Owned By Institutions | 13.00 % | |||
| Number Of Shares Shorted | 276.87 K | |||
| Price To Earning | (3.79) X | |||
| Price To Book | 1.24 X |
Thematic Opportunities
Explore Investment Opportunities
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Other Consideration for investing in VBI Stock
If you are still planning to invest in VBI Vaccines check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the VBI Vaccines' history and understand the potential risks before investing.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |